An intriguing observation is that in COVID-19 patients with T2D, the NKeff cells subset exhibits an increased presence of inhibitory receptors, specifically KIRs, and a reduced presence of activating receptors DNAM1 (CD226) and NKG2D, as opposed to patients with only COVID-19 or T2D. This evidence concerns the gene CD226 and type 2 diabetes mellitus.